公开(公告)号：FI104946B

公开(公告)日：2000-05-15

申请号：FI924817

申请日：1992-10-23

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61K9/02 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/22 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：DK0526566T3

公开(公告)日：1999-08-09

申请号：DK91909083

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61K9/02 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/22 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：NZ270871A

公开(公告)日：1999-05-28

申请号：NZ27087191

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K9/02 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：AU1125399A

公开(公告)日：1999-05-17

申请号：AU1125399

申请日：1998-10-28

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  WILSON LELAND F ,  DOHERTY PAUL C ,  HANAMOTO MARK S ,  SPIVACK ALFRED P ,  GESUNDHEIT NEIL ,  BENNETT SEAN R

IPC: A61K45/00 ,  A61K9/00 ,  A61K9/02 ,  A61K31/00 ,  A61K31/15 ,  A61K31/21 ,  A61K31/295 ,  A61K31/48 ,  A61K31/5377 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/56 ,  A61K45/06 ,  A61M31/00 ,  A61P9/12 ,  A61P15/00 ,  A61P15/02 ,  A61P21/02 ,  A61P31/00 ,  A61P43/00

Abstract: Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.

公开(公告)号：CA2305394A1

公开(公告)日：1999-05-06

申请号：CA2305394

申请日：1998-10-28

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  SMITH WILLIAM L ,  DOHERTY PAUL C JR

IPC: A61K9/02 ,  A61K31/00 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/485 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/549 ,  A61K31/5513 ,  A61K45/00 ,  A61K45/06 ,  A61P15/10 ,  A61K31/505

Abstract: A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.

公开(公告)号：CZ9703204A3

公开(公告)日：1998-05-13

申请号：CZ320497

申请日：1996-04-10

Applicant: US HEALTH ,  VIVUS INC

Inventor： KEEFER LARRY K ,  SAAVEDRA JOSEPH E ,  DOHERTY PAUL C ,  HANAMOTO MARK S ,  PLACE VIRGIL A

IPC: A61M3/00 ,  A61K31/13 ,  A61K31/44 ,  A61K31/655 ,  A61K31/785 ,  A61K47/48 ,  A61P13/02 ,  A61P15/00 ,  A61P15/10 ,  C08F8/30 ,  A61K38/00 ,  A61L27/00 ,  A61L31/00

CPC classification number: A61K31/655 ,  A61K31/785 ,  A61K47/58 ,  A61K47/59 ,  A61K47/60 ,  A61K47/64 ,  C08F8/32 ,  Y10S514/963 ,  Y10S514/968 ,  C08F112/14

公开(公告)号：NO974680L

公开(公告)日：1997-12-03

申请号：NO974680

申请日：1997-10-10

Applicant: US HEALTH ,  VIVUS INC

Inventor： KEEFER LARRY K ,  SAAVEDRA JOSEPH E ,  DOHERTY PAUL C ,  HANAMOTO MARK S ,  PLACE VIRGIL A

IPC: A61M3/00 ,  A61K31/13 ,  A61K31/44 ,  A61K31/655 ,  A61K31/785 ,  A61K47/48 ,  A61P13/02 ,  A61P15/00 ,  A61P15/10 ,  C08F8/30 ,  A61K45/00

Abstract: A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.

公开(公告)号：NO974062L

公开(公告)日：1997-09-15

申请号：NO974062

申请日：1997-09-04

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61K38/00 ,  A61F5/41 ,  A61K9/00 ,  A61K31/445 ,  A61K31/48 ,  A61K31/505 ,  A61K31/54 ,  A61K31/557 ,  A61K33/00 ,  A61K45/00 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61M31/00

Abstract: A method is provided for preventing erectile dysfunction, particularly vasculogenic impotence, in a male individual. The method involves periodic administration of a vasoactive agent throughout a 24-hour period. The agent and dosage regimen are selected such that regularly increased blood flow to the penis is achieved, in turn preventing arterial occlusion and vascular deterioration of the muscular fibers of the vessels and collagen fibers of the cavernosal tissue.

公开(公告)号：NO974062A

公开(公告)日：1997-09-15

申请号：NO974062

申请日：1997-09-04

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61K38/00 ,  A61F5/41 ,  A61K9/00 ,  A61K31/445 ,  A61K31/48 ,  A61K31/505 ,  A61K31/54 ,  A61K31/557 ,  A61K33/00 ,  A61K45/00 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61M31/00

CPC classification number: A61F5/41 ,  A61K9/0034 ,  A61M31/00 ,  A61M2210/167 ,  Y10S514/968

公开(公告)号：BR9507175A

公开(公告)日：1997-09-02

申请号：BR9507175

申请日：1995-03-20

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61B5/00 ,  A61B5/055 ,  A61B5/103 ,  A61B5/11 ,  A61B5/20 ,  A61B8/06 ,  A61F5/41 ,  A61K9/00 ,  A61K49/00 ,  A61M31/00 ,  A61B8/00 ,  A61B19/00

Abstract: A method for diagnosing vasculogenic erectile dysfunction, including vasculogenic impotence and Peyronie's syndrome, is provided. The method involves transurethral administration of a vasodilating agent to induce an erection, followed by hemodynamic evaluation using duplex ultrasonography, NMR, angiography, or the like. Kits for conducting the diagnostic method are provided as well, as are methods of treatment based on the diagnostic conclusion.